Client Situation

  • EU pharma family office with broad venture portfolio

  • Some assets close to value inflection points

  • Significant capital deployed across portfolio

  • $30m spent, $20m remaining

Treehill Mission

  • Portfolio review focused on transactability of most mature assets

  • Strategic plan to resolve gaps before transaction processes

  • Support management & board decisions to change the company’s trajectory

Findings

  • Mostly excellent science, clearly differentiated

  • Competitiveness of target product profiles limited; implications for exit structure and process

  • Several key gaps in bidder package

Recommendations & Implementation

  • Value realization strategy and tactical plans

  • Pathways to resolve regulatory, CMC and pricing gaps as relevant to the respective businesses

  • Several transactions since materialized